Drugs / Hypoestoxide
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04858074 | Jan → Sep 2022 | Parkinson disease | University of Ibadan | Completed | Missed primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Hypoestoxide | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04858074 ↗ |
| Action | Inhibit | “specifically in reducing the formation of alpha synuclein” NCT04858074 ↗ |
| Route | Oral | “4 capsules each containing 350 mg orally twice a day of PECKO-D Forte” NCT04858074 ↗ |